Selected research
Industry Research
Glutamate Receptor Ionotropic NMDA 2B Industry Research Report 2026
Market perspective
The global Glutamate Receptor Ionotropic NMDA 2B market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Glutamate Receptor Ionotropic NMDA 2B is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Glutamate Receptor Ionotropic NMDA 2B is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Glutamate Receptor Ionotropic NMDA 2B is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Glutamate Receptor Ionotropic NMDA 2B include Johnson & Johnson, Novartis AG, UCB S.A., NeurOp, Inc, Luc Therapeutics, Inc., Cerecor Inc., Bristol-Myers Squibb Company and BioCrea GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Glutamate Receptor Ionotropic NMDA 2B market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Glutamate Receptor Ionotropic NMDA 2B Market by Company
Johnson & Johnson
Novartis AG
UCB S.A.
NeurOp, Inc
Luc Therapeutics, Inc.
Cerecor Inc.
Bristol-Myers Squibb Company
BioCrea GmbH
Glutamate Receptor Ionotropic NMDA 2B Segment by Type
JNJ-0808
Radiprodil
NP-11948
NP-10679
Neu-2000
Others
Glutamate Receptor Ionotropic NMDA 2B Segment by Application
Burns
Acute Ischemic Stroke
Brain Ischemia
Autism
Others
Glutamate Receptor Ionotropic NMDA 2B Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glutamate Receptor Ionotropic NMDA 2B market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glutamate Receptor Ionotropic NMDA 2B and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glutamate Receptor Ionotropic NMDA 2B.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Glutamate Receptor Ionotropic NMDA 2B manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Glutamate Receptor Ionotropic NMDA 2B by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Glutamate Receptor Ionotropic NMDA 2B in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- JNJ-0808
- Radiprodil
- NP-11948
- NP-10679
- Neu-2000
- Others
Applications
- Burns
- Acute Ischemic Stroke
- Brain Ischemia
- Autism
- Others
Companies covered
- Johnson & Johnson
- Novartis AG
- UCB S.A.
- NeurOp, Inc
- Luc Therapeutics, Inc.
- Cerecor Inc.
- Bristol-Myers Squibb Company
- BioCrea GmbH
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Glutamate Receptor Ionotropic NMDA 2B Market Size (2021-2032)
- 2.2.2 Global Glutamate Receptor Ionotropic NMDA 2B Sales (2021-2032)
- 2.2.3 Global Glutamate Receptor Ionotropic NMDA 2B Market Average Price (2021-2032)
- 2.3 Glutamate Receptor Ionotropic NMDA 2B by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 JNJ-0808
- 2.3.3 Radiprodil
- 2.3.4 NP-11948
- 2.3.5 NP-10679
- 2.3.6 Neu-2000
- 2.3.7 Others
- 2.4 Glutamate Receptor Ionotropic NMDA 2B by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Burns
- 2.4.3 Acute Ischemic Stroke
- 2.4.4 Brain Ischemia
- 2.4.5 Autism
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Glutamate Receptor Ionotropic NMDA 2B Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Glutamate Receptor Ionotropic NMDA 2B Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Glutamate Receptor Ionotropic NMDA 2B Revenue of Manufacturers (2021-2026)
- 3.4 Global Glutamate Receptor Ionotropic NMDA 2B Average Price by Manufacturers (2021-2026)
- 3.5 Global Glutamate Receptor Ionotropic NMDA 2B Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Glutamate Receptor Ionotropic NMDA 2B, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Glutamate Receptor Ionotropic NMDA 2B, Product Type & Application
- 3.8 Global Manufacturers of Glutamate Receptor Ionotropic NMDA 2B, Established Date
- 3.9 Global Glutamate Receptor Ionotropic NMDA 2B Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Johnson & Johnson
- 4.1.1 Johnson & Johnson Company Information
- 4.1.2 Johnson & Johnson Business Overview
- 4.1.3 Johnson & Johnson Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Johnson & Johnson Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 4.1.5 Johnson & Johnson Recent Developments
- 4.2 Novartis AG
- 4.2.1 Novartis AG Company Information
- 4.2.2 Novartis AG Business Overview
- 4.2.3 Novartis AG Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis AG Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 4.2.5 Novartis AG Recent Developments
- 4.3 UCB S.A.
- 4.3.1 UCB S.A. Company Information
- 4.3.2 UCB S.A. Business Overview
- 4.3.3 UCB S.A. Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 UCB S.A. Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 4.3.5 UCB S.A. Recent Developments
- 4.4 NeurOp, Inc
- 4.4.1 NeurOp, Inc Company Information
- 4.4.2 NeurOp, Inc Business Overview
- 4.4.3 NeurOp, Inc Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 NeurOp, Inc Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 4.4.5 NeurOp, Inc Recent Developments
- 4.5 Luc Therapeutics, Inc.
- 4.5.1 Luc Therapeutics, Inc. Company Information
- 4.5.2 Luc Therapeutics, Inc. Business Overview
- 4.5.3 Luc Therapeutics, Inc. Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Luc Therapeutics, Inc. Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 4.5.5 Luc Therapeutics, Inc. Recent Developments
- 4.6 Cerecor Inc.
- 4.6.1 Cerecor Inc. Company Information
- 4.6.2 Cerecor Inc. Business Overview
- 4.6.3 Cerecor Inc. Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Cerecor Inc. Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 4.6.5 Cerecor Inc. Recent Developments
- 4.7 Bristol-Myers Squibb Company
- 4.7.1 Bristol-Myers Squibb Company Company Information
- 4.7.2 Bristol-Myers Squibb Company Business Overview
- 4.7.3 Bristol-Myers Squibb Company Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bristol-Myers Squibb Company Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 4.7.5 Bristol-Myers Squibb Company Recent Developments
- 4.8 BioCrea GmbH
- 4.8.1 BioCrea GmbH Company Information
- 4.8.2 BioCrea GmbH Business Overview
- 4.8.3 BioCrea GmbH Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 BioCrea GmbH Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 4.8.5 BioCrea GmbH Recent Developments
5 Global Glutamate Receptor Ionotropic NMDA 2B Market Scenario by Region
- 5.1 Global Glutamate Receptor Ionotropic NMDA 2B Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Glutamate Receptor Ionotropic NMDA 2B Sales by Region: 2021-2032
- 5.2.1 Global Glutamate Receptor Ionotropic NMDA 2B Sales by Region: 2021-2026
- 5.2.2 Global Glutamate Receptor Ionotropic NMDA 2B Sales by Region: 2027-2032
- 5.3 Global Glutamate Receptor Ionotropic NMDA 2B Revenue by Region: 2021-2032
- 5.3.1 Global Glutamate Receptor Ionotropic NMDA 2B Revenue by Region: 2021-2026
- 5.3.2 Global Glutamate Receptor Ionotropic NMDA 2B Revenue by Region: 2027-2032
- 5.4 North America Glutamate Receptor Ionotropic NMDA 2B Market Facts & Figures by Country
- 5.4.1 North America Glutamate Receptor Ionotropic NMDA 2B Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Glutamate Receptor Ionotropic NMDA 2B Sales by Country (2021-2032)
- 5.4.3 North America Glutamate Receptor Ionotropic NMDA 2B Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Glutamate Receptor Ionotropic NMDA 2B Market Facts & Figures by Country
- 5.5.1 Europe Glutamate Receptor Ionotropic NMDA 2B Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Glutamate Receptor Ionotropic NMDA 2B Sales by Country (2021-2032)
- 5.5.3 Europe Glutamate Receptor Ionotropic NMDA 2B Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Glutamate Receptor Ionotropic NMDA 2B Market Facts & Figures by Country
- 5.6.1 Asia Pacific Glutamate Receptor Ionotropic NMDA 2B Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Glutamate Receptor Ionotropic NMDA 2B Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Glutamate Receptor Ionotropic NMDA 2B Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Glutamate Receptor Ionotropic NMDA 2B Market Facts & Figures by Country
- 5.7.1 South America Glutamate Receptor Ionotropic NMDA 2B Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Glutamate Receptor Ionotropic NMDA 2B Sales by Country (2021-2032)
- 5.7.3 South America Glutamate Receptor Ionotropic NMDA 2B Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Glutamate Receptor Ionotropic NMDA 2B Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Glutamate Receptor Ionotropic NMDA 2B Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Glutamate Receptor Ionotropic NMDA 2B Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Glutamate Receptor Ionotropic NMDA 2B Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Glutamate Receptor Ionotropic NMDA 2B Sales by Type (2021-2032)
- 6.1.1 Global Glutamate Receptor Ionotropic NMDA 2B Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Glutamate Receptor Ionotropic NMDA 2B Sales Market Share by Type (2021-2032)
- 6.2 Global Glutamate Receptor Ionotropic NMDA 2B Revenue by Type (2021-2032)
- 6.2.1 Global Glutamate Receptor Ionotropic NMDA 2B Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Glutamate Receptor Ionotropic NMDA 2B Revenue Market Share by Type (2021-2032)
- 6.3 Global Glutamate Receptor Ionotropic NMDA 2B Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Glutamate Receptor Ionotropic NMDA 2B Sales by Application (2021-2032)
- 7.1.1 Global Glutamate Receptor Ionotropic NMDA 2B Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Glutamate Receptor Ionotropic NMDA 2B Sales Market Share by Application (2021-2032)
- 7.2 Global Glutamate Receptor Ionotropic NMDA 2B Revenue by Application (2021-2032)
- 7.2.1 Global Glutamate Receptor Ionotropic NMDA 2B Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Glutamate Receptor Ionotropic NMDA 2B Revenue Market Share by Application (2021-2032)
- 7.3 Global Glutamate Receptor Ionotropic NMDA 2B Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Glutamate Receptor Ionotropic NMDA 2B Value Chain Analysis
- 8.1.1 Glutamate Receptor Ionotropic NMDA 2B Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Glutamate Receptor Ionotropic NMDA 2B Production Mode & Process
- 8.2 Glutamate Receptor Ionotropic NMDA 2B Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Glutamate Receptor Ionotropic NMDA 2B Distributors
- 8.2.3 Glutamate Receptor Ionotropic NMDA 2B Customers
9 Global Glutamate Receptor Ionotropic NMDA 2B Analyzing Market Dynamics
- 9.1 Glutamate Receptor Ionotropic NMDA 2B Industry Trends
- 9.2 Glutamate Receptor Ionotropic NMDA 2B Industry Drivers
- 9.3 Glutamate Receptor Ionotropic NMDA 2B Industry Opportunities and Challenges
- 9.4 Glutamate Receptor Ionotropic NMDA 2B Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst